Helixmith

Helixmith

生物技术

Seoul，Korea 598 位关注者

Regenerative Medicine for Neuropathic, Neuromuscular and Neuroischemic Diseases Using a Gene Therapy Approach

关注

关于我们

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,

网站
https://www.helixmith.com/
所属行业
生物技术
规模
51-200 人
总部
Seoul，Korea
类型
上市公司
创立
1996

地点

  • 主要

    Seoul National University, 1 Gwanak-ro, Gwanak-gu

    5th Fl. Bldg. 203

    KR，Korea，Seoul，00826

    获取路线

  • 10390 Pacific Center Ct, San Diego, CA 92121

    US，CA，San Diego，92121

    获取路线

Helixmith员工

查看全部员工

相似主页

查看职位